Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings

Patients with breast cancer frequently experience financial hardship, often due to the high costs of anti-cancer drugs. We sought to develop alternative trastuzumab dosing strategies, compare their pharmacokinetic effectiveness to standard dosing, and assess the expected financial implications of tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsieh, Po-Hung, Kacew, Alec J., Dreyer, Marie, Serritella, Anthony V., Knoebel, Randall W., Strohbehn, Garth W., Ratain, Mark J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921207/
https://www.ncbi.nlm.nih.gov/pubmed/35288585
http://dx.doi.org/10.1038/s41523-022-00393-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921207/
https://www.ncbi.nlm.nih.gov/pubmed/35288585
http://dx.doi.org/10.1038/s41523-022-00393-2

Ejemplares similares